Role of Serum Chemerin in Predicting Cardiometabolic Risk: Correlation with Lipid Profile in Metabolic Syndrome

Background: Chemerin, is regarded as an adipose-derived hormone regulating insulin sensitivity, lipid homeostasis, adipogenesis and inflammatory responses. It has previously been shown that serum chemerin levels are linked to metabolic syndrome and cardio-metabolic risk. More knowledge of its associations with lipid profile components might improve early cardiometabolic risk stratification. Objective: To evaluate the association of serum chemerin as a possible biomarker for Cardiometabolic Risk (CMR) and to correlate it with lipidogram parameters in the adult population with metabolic syndrome. Methods: A case-control study with 45 individuals with metabolic syndrome and 45 healthy controls matched for age and sex. Serum chemerin concentration was assessed in fasting venous blood samples with a commercially available EC ELISA kit (BT®Chemerin ELISA Kit (China)). Using recognized enzymatic methods, the lipid profile parameters—total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)—were evaluated. Group differences and correlations were analyzed after anthropometric and clinical data were collected. Results: Patients with metabolic syndrome had considerably higher serum chemerin levels than controls (p < 0.001). Chemerin had a negative correlation with HDL-C and a positive correlation with triglycerides, total cholesterol, and LDL-C (p < 0.05 for all). Elevated levels of chemerin were consistently linked to elevated cardiometabolic risk indicators. Conclusion: Serum chemerin is a novel biomarker for predicting the risk of cardiometabolic disease and correlates with abnormalities in the lipid profile. Routine assessment of chemerin, when integrated into standard lipid profiling, may provide more insights into identifying individuals at risk for cardiometabolic diseases at an earlier stage.